JP2023534189A5 - - Google Patents

Info

Publication number
JP2023534189A5
JP2023534189A5 JP2023501424A JP2023501424A JP2023534189A5 JP 2023534189 A5 JP2023534189 A5 JP 2023534189A5 JP 2023501424 A JP2023501424 A JP 2023501424A JP 2023501424 A JP2023501424 A JP 2023501424A JP 2023534189 A5 JP2023534189 A5 JP 2023534189A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
aliphatic
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023501424A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534189A (ja
JP7867287B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/041184 external-priority patent/WO2022011318A1/en
Publication of JP2023534189A publication Critical patent/JP2023534189A/ja
Publication of JP2023534189A5 publication Critical patent/JP2023534189A5/ja
Application granted granted Critical
Publication of JP7867287B2 publication Critical patent/JP7867287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023501424A 2020-07-10 2021-07-09 Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法 Active JP7867287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063050730P 2020-07-10 2020-07-10
US63/050,730 2020-07-10
PCT/US2021/041184 WO2022011318A1 (en) 2020-07-10 2021-07-09 Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment

Publications (3)

Publication Number Publication Date
JP2023534189A JP2023534189A (ja) 2023-08-08
JP2023534189A5 true JP2023534189A5 (cg-RX-API-DMAC7.html) 2024-07-17
JP7867287B2 JP7867287B2 (ja) 2026-05-29

Family

ID=79552105

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501424A Active JP7867287B2 (ja) 2020-07-10 2021-07-09 Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法

Country Status (10)

Country Link
US (2) US20220062296A1 (cg-RX-API-DMAC7.html)
EP (1) EP4178582A4 (cg-RX-API-DMAC7.html)
JP (1) JP7867287B2 (cg-RX-API-DMAC7.html)
CN (1) CN116075302A (cg-RX-API-DMAC7.html)
AU (1) AU2021304356A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023000423A2 (cg-RX-API-DMAC7.html)
CA (1) CA3189302A1 (cg-RX-API-DMAC7.html)
IL (1) IL299754A (cg-RX-API-DMAC7.html)
MX (1) MX2023000405A (cg-RX-API-DMAC7.html)
WO (1) WO2022011318A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL294031A (en) * 2019-12-19 2022-08-01 Agenebio Inc History of benzodiazepines, preparations and methods for the treatment of cognitive impairment
IL316051A (en) * 2022-04-01 2024-11-01 Agenebio Inc Methods for preventing or slowing the progression of cognitive decline or impairment in subjects displaying normal cognitive performance
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2346500B1 (en) * 2008-10-16 2017-05-17 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US10154988B2 (en) * 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
EP4032889B1 (en) * 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Similar Documents

Publication Publication Date Title
JP3397320B2 (ja) 縮合イミダゾリウム誘導体
AU2018379992B2 (en) Nonracemic mixtures and uses thereof
JP2021528427A5 (cg-RX-API-DMAC7.html)
CN105658624B (zh) 甲酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
NZ788543A (en) Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
HUT62875A (en) Process for producing 2-aminomethyl chroman derivatives and pharmaceutical compositions comprising such compounds
WO2000075113A1 (en) Novel heterocyclic carboxamide derivatives
JP2021515029A (ja) O,o’−二置換酒石酸エナンチオマーの添加によるラセミ体ニコチンのエナンチオマー分離
JP2018521034A5 (cg-RX-API-DMAC7.html)
JP2017500334A5 (cg-RX-API-DMAC7.html)
JP2025511277A5 (cg-RX-API-DMAC7.html)
JP2013542267A5 (cg-RX-API-DMAC7.html)
MX2023014436A (es) Compuestos de 3-pirrolilsulfonamida como antagonistas de gpr17.
JP2023507569A5 (cg-RX-API-DMAC7.html)
CA3255777A1 (en) METHODS FOR PREVENTING OR SLOWING DOWN THE PROGRESSION OF COGNITIVE DECLINE OR DISORDER IN SUBJECTS WITH NORMAL COGNITIVE PERFORMANCE
JPH02193951A (ja) フルオキセチン類似体
IL299754A (en) Combinations of GABA alpha 5 agonists and SV2A inhibitors and methods of use in the treatment of cognitive impairment
MX2025006404A (es) Compuestos de pirrolil-sulfonamida fusionados
HUE029976T2 (en) New substituted isoquinoline derivatives
IE65117B1 (en) 1-(Pyridinylamino)-2-pyrrolidinones a process for their preparation and their use as medicaments
JP2016539994A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
BG100331A (bg) Фармакологично активни енантиомери
FR2877005A1 (fr) Nouveaux derives d'arylpiperazine
CN108727393B (zh) 苯基二氮杂双环衍生物及其用途
JPH04234369A (ja) 6−アルキルピリダジン誘導体、調製方法およびそれらを含有する医薬組成物